Incretin Regulation of Insulin Secretion in Monogenic Diabetes

  • Interventional
  • Recruiting
  • NCT01795144
Eligibility Details Visit Clinicaltrials.gov

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.

Monogenic diabetes patients and healthy matched controls will be admitted to the University of Chicago Clinical Resource Center for a total of 4 nights. The following will take place on separate days:

        1. Oral Glucose Tolerance Test (OGTT): consume sugary drink and blood samples will be collected at multiple time points

        2. Isoglycemic glucose infusion (IGI) test: glucose will be infused via a vein in the arm and and blood samples will be collected at multiple time points

        3. OGTT during GLP-1 infusion

        4. IGI during Exendin-9 infusion

Gender
All

Age Group
18 Years to 89 Years

Accepting Healthy Volunteers?
Accepts Healthy Volunteers

Monogenic Diabetes Subjects:

        Inclusion Criteria:

         - Diagnosis of monogenic diabetes

         - Previously participated in US Neonatal Diabetes Registry (IRB 15617B) or Genetics of diabetes mellitus (IRB 6858)

         - Age: 18 years +

        Exclusion Criteria:

         - Pregnancy

         - Acute medical illness or chronic conditions including: cardiac failure, renal insufficiency (estimated glomerular filtration rate <50 ml/min), hepatic insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease, gastrointestinal disorders causing malabsorption, anemia (Hct < 36%), or uncontrolled hypertension

        Healthy Controls:

        Inclusion Criteria:

         - Good general health

         - Stable weight for 6 months

         - Age: 18 years +

        Exclusion Criteria:

         - Pregnancy

         - Acute medical illness or chronic conditions including: cardiac failure, renal insufficiency (estimated glomerular filtration rate <50 ml/min), hepatic insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease, gastrointestinal disorders causing malabsorption, anemia (Hct < 36%), or uncontrolled hypertension

At a Glance

National Government IDNCT01795144

IRB#IRB12-1517

Lead SponsorUniversity of Chicago

Lead PhysicianSiri Greeley

Collaborator(s)N/A

EligibilityAll
18 Years to 89 Years
Recruiting